ID   YMB-1-E
AC   CVCL_2815
SY   YMB1-E; YMB1E
DR   BTO; BTO:0002583
DR   EFO; EFO_0006780
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03152043
DR   cancercelllines; CVCL_2815
DR   Cell_Model_Passport; SIDM01261
DR   ChEMBL-Cells; CHEMBL3307353
DR   ChEMBL-Targets; CHEMBL614251
DR   Cosmic; 1571791
DR   Cosmic-CLP; 1303911
DR   DepMap; ACH-002208
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GDSC; 1303911
DR   GEO; GSM1670587
DR   JCRB; JCRB0825
DR   PharmacoDB; YMB1E_1687_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_2815
DR   RCB; RCB1964
DR   TKG; TKG 0440
DR   Wikidata; Q54995446
RX   PubMed=9290701;
RX   PubMed=23136038;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Parent cell line (YMB-1) has been shown to be a ZR-75-1 derivative (PubMed=23136038).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00392.
CC   Population: Caucasian.
CC   HLA typing: A*24:18,24:18; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>T); ClinVar=VCV000375964; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.06%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=1.29%; European, North=66.59%; European, South=32.06% (PubMed=30894373).
CC   Discontinued: RCB; RCB1964; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP; JCRB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9
ST   D16S539: 11
ST   D5S818: 13
ST   D7S820: 10,11
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2814 ! YMB-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=23136038; DOI=10.1002/ijc.27931;
RA   Capes-Davis A., Reid Y.A., Kline M.C., Storts D.R., Strauss E.,
RA   Dirks W.G., Drexler H.G., MacLeod R.A.F., Sykes G.R., Kohara A.,
RA   Nakamura Y., Elmore E., Nims R.W., Alston-Roberts C., Barallon R.,
RA   Los G.V., Nardone R.M., Price P.J., Steuer A., Thomson J.A.,
RA   Masters J.R.W., Kerrigan L.;
RT   "Match criteria for human cell line authentication: where do we draw
RT   the line?";
RL   Int. J. Cancer 132:2510-2519(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//